Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Reduction of liver metastasis in colon cancer

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

News image

Advanced and recurrent diseases are the major causes of death in colon cancer.

No standard preclinical model addresses advanced disease and spontaneous metastasis after orthotopic tumor growth.

Dr Christina Hackl from Canada report on the establishment of such standardized orthotopic mouse models of colon cancer, and their use in evaluating metronomic topotecan alone or in combination with standard chemotherapy.

Design Human colon cancer cell lines, transfected with human chorionic gonadotropin and luciferase, were injected orthotopically into the cecal wall of severe combined immunodeficient mice, intrasplenically or subcutaneously.

For adjuvant therapy, cecal resections were performed 3–5 weeks after tumor cell injection.

Chemotherapy drugs tested included uracil/tegafur, folinic acid, oxaliplatin, topotecan, pazopanib and various combinations.

Subcutaneous tumors showed exaggerated sensitivity to treatment
Gut

The researchers found that subcutaneous tumors showed exaggerated sensitivity to treatment by delayed tumor growth and increased survival, but no metastatic spread.

Intrasplenic cell injection resulted in rapid and extensive but artefactual metastasis without treatment effect.

The research team found that intracecal cell injection with tumor take rates of 88–100% showed spontaneous metastases at clinically relevant rates.

Metronomic topotecan significantly polonged survival and reduced metastasis.

In the adjuvant setting, metronomic maintenance therapy prolonged survival compared with vehicle controls, control followed by topotecan or FOLFOX-like therapy.

Dr Hackl's team commented, "The refined orthotopic implantation technique proved to be a clinically relevant model for metastasis and therapy studies."

"Furthermore, metronomic therapy with oral topotecan may be promising to consider for clinical trials of metastatic colon cancer and long-term adjuvant maintenance therapy of colon cancer."  

Gut  2013;62:259-271
21 January 2013

Go to top of page Email this page Email this page to a colleague

 30 June 2015

Advanced search
 30 June 2015 
NSAIDs and hearburn symptoms
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 29 June 2015 
Rescue therapy in ulcerative colitis
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Fecal microbiota in pediatric IBD
 24 June 2015 
Environmental risk in IBD
 24 June 2015 
Fatigue scales for IBD
 24 June 2015 
Mucosal healing tests in ulcerative colitis
 23 June 2015 
Marker associated with endoscopic lesion in Crohn's
 23 June 2015 
Body composition in children with IBD
 23 June 2015 
Medical vs nurse endoscopists
 22 June 2015 
Gene polymorphism associated with increased liver enzymes
 22 June 2015 
Treatment of uncomplicated acute appendicitis
 22 June 2015 
Solid organ cancers after liver transplant
 19 June 2015 
Causes of death in HBV
 19 June 2015 
Lifetime benefits of increased adenoma detection rates
 19 June 2015 
Acid-suppressive therapy before anti-reflux surgery
 18 June 2015 
Endoscopic activity in symptomatic IBD patients
 18 June 2015 
Regimens for H. pylori eradication
 18 June 2015 
Risk for dyspepsia
 17 June 2015 
Non-invasive markers of advanced liver fibrosis
 17 June 2015 
Patients’ and clinicians’ perception of pouch dysfunction
 17 June 2015 
NAFLD risk in celiac disease
 16 June 2015 
Esophageal food bolus impaction
 16 June 2015 
Evaluating lymph node metastasis for rectal cancer
 16 June 2015 
Risk score for hepatocellular carcinoma screening
 15 June 2015 
Low-cost colonoscopy training
 15 June 2015 
Determining dysbiosis in IBS or IBD
 15 June 2015 
Light alcohol consumption and NAFLD
 12 June 2015 
Smoking and disease course in IBD
 12 June 2015 
Hep D in a Hep B endemic area
 12 June 2015 
Patient-orientated internet information in ulcerative colitis
 11 June 2015 
Physical inactivity and NAFLD
 11 June 2015 
Esophageal stricture after endoscopic resection
 11 June 2015 
Guideline based screening strategies for hepatitis
 10 June 2015 
Cost-effectiveness of HCV treatment in liver disease
 10 June 2015 
Abdominoperineal excision for low rectal cancer
 10 June 2015 
Pediatric chronic Hep C
 09 June 2015 
Bile acid malabsorption in IBS
 09 June 2015 
Racial differences in celiac disease
 09 June 2015 
Conversion from laparoscopic to open colorectal cancer resection
 08 June 2015 
Short sleep duration and NAFLD
 08 June 2015 
Heritability in inflammatory bowel disease
 08 June 2015 
Eosinophilic esophagitis
 05 June 2015 
In-hospital mortality in patients with lower GI bleeding
 05 June 2015 
Scoring system for microscopic colitis
 05 June 2015 
H. pylori and myocardial infarction
 04 June 2015 
Mucosal healing in celiac disease and pregnancy
 04 June 2015 
Gastrointestinal microbiomes in Crohn's
 04 June 2015 
Dyspepsia in the community:
 03 June 2015 
Predicting disease activity in IBD
 03 June 2015 
Outcomes with discontinuation of therapy in Crohn's
 03 June 2015 
Biopsies in eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us